PLK2 and osteosarcoma: Finally, integrating the site predictions with the kinase characteristics, DNA states, and face accessibility, we hypothesized that in osteosarcoma, PLK2 phosphorylates Ser48 of TAp73, which acts as a tumor suppressor to inhibit TAp73 function (Fig. 1D, details in Supplementary Information).